Eleven-Year Follow-up of Idiotype Vaccine and DA-EPOCH-Rituximab in Untreated Mantle Cell Lymphoma: Correlation of Survival with Idiotype Immune Response

被引：4

作者：

Grant, Cliona

Neelapu, Sattva S. ^{[2
,3
]}

Kwak, Larry W.

Dunleavy, Kieron

White, Therese

Miller, Barry W.

Jaffe, Elaine S. ^{[1
]}

Steinberg, Seth M. ^{[4
]}

Bird, Brian Healey ^{[5
]}

Wilson, Wyndham H. ^{[6
]}

机构：

[1] NCI, Ctr Canc Res, Pathol Lab, Bethesda, MD 20892 USA

[2] UT MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA

[3] UT MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX USA

[4] NCI, Biostat & Data Management Sect, NIH, Rockville, MD USA

[5] Bons Secours Hosptial, Cork, Ireland

[6] NCI, Metab Branch, NIH, Bethesda, MD 20892 USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

10.1182/blood.V118.21.2707.2707

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1164 / 1165

页数：2

共 29 条

[21] First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
Flinn, Ian W.
van der Jagt, Richard
Kahl, Brad
Wood, Peter
Hawkins, Tim
MacDonald, David
Simpson, David
Kolibaba, Kathryn
Issa, Samar
Chang, Julie
Trotman, Judith
Hallman, Doreen
Chen, Ling
Burke, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (12) : 984 - +
[22] Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
Chihara, Dai
Cheah, Chan Y.
Westin, Jason R.
Fayad, Luis E.
Rodriguez, Maria A.
Hagemeister, Fredrick B.
Pro, Barbara
McLaughlin, Peter
Younes, Anas
Samaniego, Felipe
Goy, Andre
Cabanillas, Fernando
Kantarjian, Hagop
Kwak, Larry W.
Wang, Michael L.
Romaguera, Jorge E.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (01) : 80 - 88
[23] Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results
Tobinai, Kensei
Ogura, Michinori
Itoh, Kuniaki
Kinoshita, Tomohiro
Hotta, Tomomitsu
Watanabe, Takashi
Morishima, Yasuo
Igarashi, Tadahiko
Terauchi, Takashi
Ohashi, Yasuo
CANCER SCIENCE, 2010, 101 (12) : 2579 - 2585
[24] Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC Plus autologous stem-cell support: still very long survival but late relapses do occur (vol 158, pg 355, 2012)
Geisler, Christian H.
Kolstad, Arne
Laurell, Anna
Jerkeman, Mats
Raty, Riikka
Andersen, Niels S.
Pedersen, Lone B.
Eriksson, Mikael
Nordstrom, Marie
Kimby, Eva
Bentzen, Hans
Kuittinen, Outi
Lauritzsen, Grete F.
Nilsson-Ehle, Herman
Ralfkiaer, Elisabeth
Ehinger, Mats
Sundstrom, Christer
Delabie, Jan
Karjalainen-Lindsberg, Marja-Liisa
Brown, Peter
Elonen, Erkki
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (06) : 815 - 816
[25] Durable event-free and overall survival (EFS/OS) in mantle cell lymphoma (MCL) without rituximab: Long-term follow-up ofa phase II trial with intensive chemotherapy (CTAP/VMAC) followed by autologous hematopoietic stem cell transplant (aHSCT).
Evens, Andrew M.
Winter, Jane N.
Hou, Nanjiang
Rademaker, Fred
Kelemen, Katalin
Nelson, Beverly
Patton, David
Frankfurt, Olga
Williams, Stephanie
Singhal, Seema
Tallman, Martin S.
Rosen, Steven T.
Mehta, Jayesh
Gordon, Leo I.
BLOOD, 2006, 108 (11) : 693A - 693A
[26] Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
Qin, Yan
Song, Yongping
Wang, Dong
Bai, Ou
Feng, Jifeng
Sun, Xiuhua
Qiu, Lihua
Yang, Jianmin
Yang, Yu
Wang, Zhao
Hu, Jianda
Wang, Huaqing
Su, Hang
Jin, Zhengming
Qian, Wenbin
Jin, Chuan
Zhang, Mingzhi
Yu, Ding
Liu, Li
Chen, Guoan
Li, Yarong
Sun, Tao
Jin, Jie
Bao, Huizheng
Du, Xin
Zhou, Hui
Fu, Gan
Shi, Yuankai
BMC CANCER, 2024, 24 (01)
[27] Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
Yan Qin
Yongping Song
Dong Wang
Ou Bai
Jifeng Feng
Xiuhua Sun
Lihua Qiu
Jianmin Yang
Yu Yang
Zhao Wang
Jianda Hu
Huaqing Wang
Hang Su
Zhengming Jin
Wenbin Qian
Chuan Jin
Mingzhi Zhang
Ding Yu
Li Liu
Guoan Chen
Yarong Li
Tao Sun
Jie Jin
Huizheng Bao
Xin Du
Hui Zhou
Gan Fu
Yuankai Shi
BMC Cancer, 24
[28] Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon a-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study
Yan, Gao
Wu, Jianqiu
Huang, Yunhong
Zhou, Hui
Feng, Ru
Li, Fei
Li, Xue-Ping
Wang, Xiaoxiao
Bai, Bing
Huang, Yu-Hua
He, Haixia
Ping, Liqin
He, Yanxia
Huang, Cheng
Li, Jibin
Mao, Jiaying
Huang, Huiqiang
BLOOD, 2023, 142
[29] Nordic mantle cell lymphoma (MCL) project: Prolonged follow-up of 86 patients treated with BEAM/BEAC plus PBSCT confirms that addition of high-dose ara-c and rituximab to CHOP induction plus in-vivo purging with rituximab increases clinical and molecular response rates, PCR-Neg. Grafts, failure-free, relapse-free and overall survival.
Geisler, CH
Elonen, E
Kolstad, A
Laurell, A
Andersen, NS
Pedersen, LB
Jerkeman, M
Nordstroem, M
Lauritzen, GF
Ralfkiaer, E
Aakerman, M
Sundstroem, C
Langholm, R
Karjalainen-Lindsberg, ML
BLOOD, 2004, 104 (11) : 6A - 6A

← 1 2 3 →